Skip to main content
. Author manuscript; available in PMC: 2015 Oct 2.
Published in final edited form as: Pharmacol Ther. 2014 Jun 16;144(3):268–282. doi: 10.1016/j.pharmthera.2014.06.006

Fig.3.

Fig.3

Potential mechanisms of synucleinopathy-induced augmentation of DOPAL production. Synucleinopathy might increase DOPAL formation by inhibiting VMAT2 expression or functions, permeabilizing vesicles, interfering with axonal transport (thereby decreasing vesicle numbers in striatal dopaminergic terminals), and inhibiting exocytosis.